[A24-27] Nirsevimab (prevention of RSV disease) – Benefit assessment according to §35a Social Code Book V
Last updated 15.08.2024
Project no.:
A24-27
Commission:
Commission awarded on 04.03.2024 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Children during their 1st RSV season with indication for secondary prophylaxis of lower respiratory tract infections caused by respiratory syncytial virus.
- Children in whom palivizumab is indicated: added benefit not proven
- Children in whom palivizumab is not indicated: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2024-07-18.
https://doi.org/10.60584/A24-27_en
| Project no. | Title | Status |
|---|---|---|
| A24-75 | Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease) - Addendum to Project A24-27 | Commission completed |
| A24-82 | Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease, 2nd. RSV season) – Benefit assessment according to §35a Social Code Book (SGB) V | Commission completed |
| A25-33 | Nirsevimab (prevention of RSV lower respiratory tract disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-08-15 A G-BA decision was published.